Baseline characteristics in the AMI cohort
| Variable, n (%) | AMI population N=7467 | Men N=5630 (75.4%) | Women N=1837 (24.6%) |
| Age, median (IQR) | 66 (15) | 65 (14) | 69 (14) |
| Age group | |||
| <35 years | 32 (0.4) | 29 (0.5) | 3 (0.2) |
| 35–49 years | 676 (9.1) | 566 (10.0) | 110 (5.9) |
| 50–64 years | 2781 (37.2) | 2254 (40.0) | 527 (28.6) |
| 65–80 years | 3978 (53.3) | 2781 (49.3) | 1197 (65.1) |
| Type of AMI | |||
| Type 1 AMI | 6790 (90.9) | 5216 (92.6) | 1574 (85.7) |
| Type 2 AMI | 226 (3.0) | 123 (2.2) | 103 (5.6) |
| Type 3–5 AMI | 329 (4.4) | 203 (3.6) | 126 (6.9) |
| Data not available in SWEDEHEART | 122 (1.6) | 88 (1.6) | 34 (1.9) |
| NSTEMI/STEMI classification | |||
| NSTEMI | 5410 (72.5) | 4037 (71.7) | 1373 (74.7) |
| STEMI | 1725 (23.1) | 1382 (24.5) | 343 (18.7) |
| Data not available in SWEDEHEART | 332 (4.4) | 211 (3.7) | 121 (6.6) |
| Arrived at ED by ambulance | 3595 (48.1) | 2601 (46.2) | 994 (54.1) |
| Index AMI coronary reperfusion (PCI or CABG) | 5594 (74.9) | 4474 (79.5) | 1120 (61.0) |
| Comorbidities recorded at index AMI | |||
| Diabetes | 1359 (18.2) | 1020 (18.1) | 339 (18.5) |
| History of prior AMI | 1075 (14.4) | 834 (14.8) | 241 (13.1) |
| History of prior stroke | 350 (4.7) | 253 (4.5) | 97 (5.3) |
| Chronic kidney disease | 201 (2.7) | 141 (2.5) | 60 (3.3) |
| Heart failure | 244 (3.3) | 167 (3.0) | 77 (4.2) |
| Peripheral artery disease | 118 (1.6) | 87 (1.5) | 31 (1.7) |
| Medication prescribed at index AMI discharge and continued for ≥6 months | |||
| Aspirin | 7018 (94.0) | 5326 (94.6) | 1692 (92.1) |
| P2Y12 inhibitors* | 6805 (91.1) | 5212 (92.6) | 1593 (86.7) |
| Clopidogrel | 3555 (47.6) | 2618 (46.5) | 937 (51.0) |
| Prasugrel | 105 (1.4) | 80 (1.4) | 25 (1.4) |
| Ticagrelor | 3553 (47.6) | 2825 (50.2) | 728 (39.6) |
| Beta blockers | 6980 (93.5) | 5274 (93.7) | 1706 (92.9) |
| ACE inhibitors/ARB | 6064 (81.2) | 4621 (82.1) | 1443 (78.6) |
| Statins | 7081 (94.8) | 5397 (95.9) | 1684 (91.7) |
*Some patients switched between different types of P2Y12 inhibitors during the study period.
ACE/ARB, angiotensin-converting enzyme/angiotensin II receptor blockers; AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; ED, emergency department; NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary intervention; SWEDEHEART, Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies Registry.